Different pharmacokinetics of nicotine following intravenous administration of nicotine base and nicotine hydrogen tartarate in rats

被引:35
作者
Jung, BH
Chung, BC
Chung, SJ
Shim, CK
机构
[1] Seoul Natl Univ, Coll Pharm, Dept Pharmaceut, Seoul 151742, South Korea
[2] Korea Inst Sci & Technol, Bioanal & Biotransformat Res Ctr, Seoul 130650, South Korea
关键词
nicotine; nicotine base; nicotine hydrogen tartarate; cotinine; pharmacokinetics;
D O I
10.1016/S0168-3659(01)00452-7
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Pharmacokinetics of nicotine was studied in rats following intravenous (i.v.) administration of nicotine base (NB) and nicotine hydrogen tartarate salt (NS) at a nicotine dose of 1 mg/kg. The area under the plasma concentration-time curve (AUC), mean residence time (MRT), systemic clearance (CL), distribution volume at steady state (V-ss) and terminal plasma half-life (T-1/2,T-beta) of nicotine were compared between NB and NS. Compared to NS, NB exhibited higher and sustained plasma nicotine levels, thereby yielding significantly (P<0.05) larger AUC (66.3 vs. 27.7 μg ml/min), MRT (165.7 vs. 58.3 min), T-1/2,T-β (144.2 vs. 51.4 min) and a lower CL (18.3 vs. 46.3 ml/min per kg). The V-ss was comparable between the two compounds. The metabolic conversion to cotinine front NS was threefold larger than that from NB. The plasma protein binding and distribution to blood cells were comparable between the compounds. The apparent partition coefficient (APC) of NS decreased as a function of its concentration, while that of NB remained nearly constant. Particles of different mean sizes were observed for the 1% (w/v) aqueous solutions of NS (388.6 nm) and NB (123.8 nm). Different metabolism and/or elimination between NB and NS appear to be mainly responsible for their different pharmacokinetics. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:183 / 190
页数:8
相关论文
共 27 条
[1]  
BARN JA, 1988, NEUROLOGY, V361, P490
[2]   Sources of variability in nicotine and cotinine levels with use of nicotine nasal spray, transdermal nicotine, and cigarette smoking [J].
Benowitz, NL ;
Zevin, S ;
Jacob, P .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 43 (03) :259-267
[3]  
BENOWITZ NL, 1988, NEW ENGL J MED, V319, P1318
[4]  
BOWMAN ER, 1959, J PHARMACOL EXP THER, V127, P92
[5]  
FERRE M, 1991, BR J ADDICT, V86, P1601
[6]   NICOTINE PHARMACOKINETICS AND ITS APPLICATION TO INTAKE FROM SMOKING [J].
FEYERABEND, C ;
INGS, RMJ ;
RUSSELL, MAH .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 19 (02) :239-247
[7]   PHARMACOLOGY OF CIGARETTE-SMOKING BEHAVIOR [J].
GRIFFITHS, RR ;
HENNINGFIELD, JE .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1982, 3 (06) :260-263
[8]   SINGLE-DOSE AND MULTIPLE-DOSE PHARMACOKINETICS OF NICODERM(R) (NICOTINE TRANSDERMAL SYSTEM) [J].
GUPTA, SK ;
OKERHOLM, RA ;
COEN, P ;
PRATHER, RD ;
GORSLINE, J .
JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 33 (02) :169-174
[9]   NICOTINE DELIVERY KINETICS AND ABUSE LIABILITY [J].
HENNINGFIELD, JE ;
KEENAN, RM .
JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY, 1993, 61 (05) :743-750
[10]   KINETIC EVALUATION OF TRANSDERMAL NICOTINE DELIVERY SYSTEMS [J].
HO, H ;
CHIEN, YW .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1993, 19 (03) :295-313